WebJan 6, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel ® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential ... WebTrial Description. 3. NCT03394365. Tabelecleucel for Solid Organ Transplant (SOT) subjects after failure of rituximab or rituximab and chemotherapy, and in Hematopoietic Cell Transplant (HCT) subjects after failure of rituximab (ALLELE) 2. NCT04554914. A Study to Evaluate Tabelecleucel in Participants With Epstein-Barr Virus-associated Diseases.
Atara Biotherapeutics Announces Positive Results from
WebDec 17, 2024 · Atara's lead indication is rituximab refractory patients with Epstein Barr Virus associated post-transplant lymphoproliferative diseases, or EBV+PTLD. Lead asset is tabelecleucel (tab-cel), an ... WebJan 4, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel ® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-positive post … south lake tahoe dixie boat cruise
Atara Biotherapeutics Announces Positive Results from ... - BioSpace
WebJan 10, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential ... WebJun 7, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant … WebMay 30, 2024 · Atara Biotherapeutics’s investigative therapy Tab-cel (tabelecleucel) is a potentially safe and viable option to treat transplant-derived lymphoma, according to long-term data from two Phase 2 clinical trials.. The new results will be presented in a poster titled, “ Long Term Outcomes of Tabelecleucel (Allogeneic Third-Party EBV-Targeted … teaching financial management to teens